An alternative reduced dose regimen of ticagrelor for neuroendovascular patients.
Omar Kass-HoutJoseph SternRuth D TangonanRami Z MorsiSonam ThindTareq Kass-HoutLee GutermanPublished in: Vascular (2022)
testing and who have increased risk of ischemic or hemorrhagic strokes due to neurovascular pathologies and implants. Further randomized studies are required to confirm these findings.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute coronary syndrome
- prognostic factors
- open label
- randomized controlled trial
- patient reported outcomes
- oxidative stress
- st elevation myocardial infarction
- ischemia reperfusion injury
- phase ii
- case control
- study protocol
- atrial fibrillation
- cerebral ischemia